A 24-week, Open, Multicenter, Comparative Study of 2 Strategies (Including Insulin Glargine Versus Premixed Insulin) for the Therapeutic Management of Patients With Type 2 Diabetes Failing Oral Agents.

Trial Profile

A 24-week, Open, Multicenter, Comparative Study of 2 Strategies (Including Insulin Glargine Versus Premixed Insulin) for the Therapeutic Management of Patients With Type 2 Diabetes Failing Oral Agents.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary) ; Insulin aspart/insulin protamine aspart; Insulin neutral protamine lispro/insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GALAPAGOS
  • Sponsors Sanofi
  • Most Recent Events

    • 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
    • 15 Mar 2013 New source identified and integrated (Clinical Trials Registry - India; CTRI2010-091-001386).
    • 02 Mar 2012 Actual patient number (934) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top